remaining questions on the use of neoadjuvant pembrolizumab in early tnbc following keynote-522
Published 2 years ago • 370 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
1:42
the case for neoadjuvant pembrolizumab in tnbc
-
3:09
keynote-522: neoadjuvant and adjuvant pembrolizumab for early tnbc
-
4:17
keynote-522: efs sensitivity & subgroup analyses
-
2:53
neoadjuvant chemoimmunotherapy: keynote-522, i-spy & more
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
0:57
a post hoc analysis of adjuvant radiation therapy in the keynote-522 study
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
3:49
keynote-522: neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs place...
-
1:43
dr. rugo on the results of the keynote-522 trial in tnbc
-
4:53
chemoimmunotherapy in tnbc: the keynote-355 trial
-
4:01
fda d.i.s.c.o. burst edition: fda approval of keytruda (pembrolizumab) for high-risk early-stage ...
-
1:20
neopele: neoadjuvant pembrolizumab and lenvatinib in resectable stage iii melanoma
-
7:15
pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembr...
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
6:02
ev-103: ev pembrolizumab as a promising first-line option for urothelial carcinoma
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
1:58
ascent-04: sacituzumab govitecan and pembrolizumab in pd-l1-positive tnbc